These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2645071)

  • 1. Selective elimination of autoreactive lymphocytes with immunotoxins.
    Krolick KA
    Clin Immunol Immunopathol; 1989 Mar; 50(3):273-82. PubMed ID: 2645071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
    Byers VS; Baldwin RW
    Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotoxins: current use and future prospects in bone marrow transplantation and cancer treatment.
    Neville DM
    Crit Rev Ther Drug Carrier Syst; 1986; 2(4):329-52. PubMed ID: 3549005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressor deletion therapy. Selective elimination of T suppressor cells using a hematoporphyrin-conjugated monoclonal antibody.
    Steele JK; Liu D; Stammers AT; Deal H; Whitney S; Levy JG
    Targeted Diagn Ther; 1988; 1():157-89. PubMed ID: 2980947
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting T cells for GVHD therapy.
    Vallera DA
    Semin Cancer Biol; 1996 Apr; 7(2):57-64. PubMed ID: 8740560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor T lymphocyte infusion following ex vivo depletion of donor anti-host reactivity by a specific anti-interleukin-2 receptor P55 chain immunotoxin.
    André-Schmutz I; Le Deist F; Hacein-Bey S; Hamel Y; Vitetta E; Schindler J; Fischer A; Cavazzana-Calvo M
    Transplant Proc; 2002 Nov; 34(7):2927-8. PubMed ID: 12431660
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunotoxins for the therapy of graft versus host disease.
    Salzman D; LeMaistre F
    Cancer Treat Res; 1993; 68():133-44. PubMed ID: 8105848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective killing of T cells by immunotoxins directed at distinct V beta epitopes of the T cell receptor.
    Rigaut KD; Scharff JE; Neville DM
    Eur J Immunol; 1995 Jul; 25(7):2077-82. PubMed ID: 7542605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation.
    Bastien JP; Roy J; Roy DC
    Semin Oncol; 2012 Dec; 39(6):674-82. PubMed ID: 23206844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell depletion and graft survival induced by anti-human CD3 immunotoxins in human CD3epsilon transgenic mice.
    Weetall M; Digan ME; Hugo R; Mathew S; Hopf C; Tart-Risher N; Zhang J; Shi V; Fu F; Hammond-McKibben D; West S; Brack R; Brinkmann V; Bergman R; Neville D; Lake P
    Transplantation; 2002 May; 73(10):1658-66. PubMed ID: 12042656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Basic concept and clinical application of monoclonal antibody].
    Nihon Rinsho; 1990 Aug; 48 Suppl():938-1124. PubMed ID: 2232229
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease.
    Weinberg AD
    Mol Med Today; 1998 Feb; 4(2):76-83. PubMed ID: 9547794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How does B cell depletion therapy work, and how can it be improved?
    Clark EA; Ledbetter JA
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv77-80. PubMed ID: 16239394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for the use of immunotoxins in the treatment of HIV-infected humans.
    Van Oijen MG; Preijers FW
    J Drug Target; 1998; 5(2):75-91. PubMed ID: 9588864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of graft-versus-host disease by using immunotoxins.
    Laurent G; Bouloux C
    Prog Clin Biol Res; 1992; 377():129-36; discussion 137. PubMed ID: 1438408
    [No Abstract]   [Full Text] [Related]  

  • 17. Pretreatment of kidney allografts with anti-CD5 immunotoxin: a new chance for high responder recipients.
    Alexeev LP; Toptygin AYu ; Korenkova EV; Yan G Moisiuk Y; Muromtseva IB; Tonevitsky AG; Dolbin AG; Sechkin AV; Shumakov VI; Vasilov RG; Khaitov RM
    Transplant Proc; 1997 Dec; 29(8):3605-6. PubMed ID: 9414856
    [No Abstract]   [Full Text] [Related]  

  • 18. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin.
    Roy DC; Ouellet S; Le Houillier C; Ariniello PD; Perreault C; Lambert JM
    J Natl Cancer Inst; 1996 Aug; 88(16):1136-45. PubMed ID: 8757193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotoxins and central nervous system neoplasia.
    Hall WA; Fodstad O
    J Neurosurg; 1992 Jan; 76(1):1-12. PubMed ID: 1727147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts.
    Henslee PJ; Byers VS; Jennings CD; Marciniak E; Thompson JS; Macdonald JS; Romond EH; Messino MJ; Scannon PJ
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3004-7. PubMed ID: 2650413
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.